Non-alcoholic Fatty Liver Diseases (NAFLD) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Diagnostic performance of the GGT/HDL-C ratio for NAFLD in adults with obesity undergoing bariatric surgery
Non-alcoholic fatty liver disease (NAFLD) is the accumulation of fat in the liver, known as liver steatosis, in individuals who do not consume excessive amounts of alcohol and for whom secondary causes have been excluded [1]. This broad clinical spectrum ranges from benign or simple liver steatosis (NAFL) to non-alcoholic steatohepatitis (NASH), progressing to fibrosis and cirrhosis, and, ultimately, hepatocellular carcinoma (HCC) [2]. NAFLD has become the most common liver disease and affects a quarter of the global adult population. (Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - April 2, 2024 Category: Endocrinology Authors: Renzo Pajuelo-Vasquez, Jerry K. Benites-Meza, Hilda V. Durango-Chavez, Gustavo Salinas-Sedo, Carlos J. Toro-Huamanchumo Source Type: research

A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
(Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy)
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - April 1, 2024 Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity Source Type: research

Epidemiology of NAFLD – Focus on diabetes
There is increasing appreciation of the complex interaction between nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D) and insulin resistance. Not only is the prevalence of NAFLD disease high among patients with T2D, the liver disease is also more progressive. Currently, the global prevalence of NAFLD in the general population (2016 –2019) is 38 %. The prevalence of T2D among those with NAFLD is approximately 23 % while the prevalence of NAFLD among those with T2D can be as high as 70 %. (Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - April 1, 2024 Category: Endocrinology Authors: Zobair M. Younossi, Linda Henry Source Type: research

The Impact of Non-alcohol Fatty Liver Disease on Bone Mineral Density is Mediated by Sclerostin by Mendelian Randomization Study
AbstractNon-alcoholic fatty liver disease (NAFLD) has been found to be associated with osteoporosis (OP) in observational studies. However, the precise causal relationship between NAFLD and OP remains unclear. Here, we used Mendelian randomization (MR) to explore the causal relationship. We selected NAFLD-related single-nucleotide polymorphisms from a genome-wide meta-analysis (8434 cases and 434,770 controls) as instrumental variants. We used inverse variance weighted analysis for the primary MR analysis. Furthermore, we used similar methodologies in parallel investigations of other chronic liver diseases (CLDs). We perfo...
Source: Calcified Tissue International - March 31, 2024 Category: Orthopaedics Source Type: research